Printer Friendly

FORMER SENIOR DIRECTOR OF BRISTOL-MYERS SQUIBB APPOINTED V.P. PHARMACEUTICAL DEVELOPMENT & MEDICAL AFFAIRS AT BIORELEASE TECHNOLOGIES

 SALEM, N.H., Feb. 1 /PRNewswire/ -- Biorelease Technologies, Inc., the operating subsidiary of Biorelease Corp. (NASDAQ: BREL), today announced that it has appointed Sheldon E. Schwartz, M.D. to the newly created position of vice president -- pharmaceutical development and medical affairs. Dr. Schwartz joins Biorelease with extensive pharmaceutical product development expertise, including seven years in senior management positions at Bristol-Myers Squibb. Dr. Schwartz supervised European clinical research for Bristol-Myers Squibb's products in cardiovascular, central nervous system, gastrointestinal and metabolic diseases, infectious disease, and oncology.
 "The appointment of Dr. Schwartz represents a major milestone in building our company's pharmaceutical product business. By applying his 10 years of pharmaceutical industry experience and his medical expertise, he will lead our efforts to develop therapeutic drug products based on our proprietary chondroitin sulfate technology," said R. Bruce Reeves, Ph.D., chief operating officer of Biorelease. "Dr. Schwartz is joining us at a particularly appropriate time," Dr. Reeves added, "since we are now ready to intensify our drug development activities."
 In his position at Biorelease, Dr. Schwartz will direct all the company's drug development programs, including pharmacology and preclinical studies. In addition, he will be responsible for the company's regulatory affairs, and for identifying and assessing technologies that could be inlicensed to complement and enhance the company's hemoglobin-based chondroitin sulfate-based carrier technologies.
 Dr. Schwartz, 46, joins Biorelease from Sepracor, where he had held the position of corporate medical director and director of clinical research. From 1983 to 1990, Dr. Schwartz held a number of positions at Bristol-Myers Squibb, most recently as senior director, in which he was responsible for procedures for worldwide developmental planning for the research and development division. He first served as Bristol-Myers Squibb's director of clinical research for gastrointestinal and metabolic diseases.
 Dr. Schwartz, a gastroenterologist, received his M.D. at the New York University School of Medicine. He was a tenured associate professor of medicine at the State University of New York-Upstate Medical Center in Syracuse, and he has published widely in the scientific literature in the area of gastrointestinal physiology.
 Biorelease Technologies, Inc., the operating subsidiary of Biorelease Corp., is dedicated to commercializing proprietary cell-culture additives and developing pharmaceutical applications of its hemoglobin- based and chondroitin sulfate-based carrier technologies. The company is headquartered in Salem, New Hampshire.
 -0- 2/1/93
 /CONTACT: R. Bruce Reeves, chief operating officer of Biorelease, 603-893-7300; or Marcia A. Kean, executive V.P. of Feinstein Partners, 617-577-8110, for Biorelease/
 (BREL)


CO: Biorelease Technologies, Inc. ST: New Hampshire IN: MTC SU: PER

DH -- NE008 -- 1202 02/01/93 09:16 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 1, 1993
Words:425
Previous Article:POLYCOM REPORTS BEST UNIT SALES IN AUDIOCONFERENCING INDUSTRY IN FIRST QUARTER OF PRODUCTION; ADVANCED AUDIO TECHNOLOGY BREAKS OPEN MARKET
Next Article:NEW ENGLAND GOVERNORS' CONFERENCE, INC. SUPPORTS NORTHEAST INTERSTATE DAIRY COMPACT
Topics:


Related Articles
IXSYS AND BRISTOL-MYERS SQUIBB ANNOUNCE RESEARCH AGREEMENT ON TUMOR-ASSOCIATED ANTIBODIES
IXSYS AND BRISTOL-MYERS SQUIBB ANNOUNCE RESEARCH AGREEMENT ON TUMOR-ASSOCIATED ANTIBODIES
BRISTOL-MYERS SQUIBB PHARMACEUTICAL
DR. SHARON HENRY OF BRISTOL-MYERS SQUIBB COMPANY RECEIVES HEALTH WATCH'S FIRST WOMEN'S LEADERSHIP AWARD
BRISTOL-MYERS SQUIBB TAKES EQUITY POSITION IN IXSYS -- WILL FUND THREE-YEAR R&D PROGRAM
Bristol-Myers Squibb and Cadus Extend Research Collaboration; BMS Has Confirmed 'Hits' With Cadus Drug Discovery Screens
Advanced Magnetics, Inc. Elects Two New Members to Board of Directors
Bristol-Myers Squibb and Progenics Pharmaceuticals Announce Licensing Agreement for Cancer Vaccines
Integra LifeSciences Reverse Stock Split Approved

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters